CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

INSIDE INFORMATION
FILING WITH THE CSRC FOR PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by CF PharmTech, Inc. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated November 25, 2025 (the "**Announcement**") in relation to the Company's proposed implementation of the H share full circulation. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on January 12, 2026, the Company has submitted a filing application to the CSRC in relation to the proposed implementation of the H Shares Full Circulation for the conversion of 107,408,422 domestic unlisted Shares (the "**Unlisted Shares**") into H Shares on a one-for-one basis. Upon completion of all the filing requirements (including the filing with the CSRC) and obtaining all the relevant approvals (including the approval of the Conversion and Listing by the Stock Exchange) and compliance with all applicable laws, regulations and rules, 107,408,422 Unlisted Shares will be converted into 107,408,422 H Shares, which will be listed and traded on the Stock Exchange.

As at the date of this announcement, the Company has not yet applied to the Stock Exchange for the Conversion and Listing, and the details of the Company's implementation plan in relation to H Share Full Circulation and the Conversion and Listing have not yet been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in compliance with the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, January 12, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.